The approval of a controversial new drug for Alzheimer’s disease, Aduhelm, is shining a spotlight on mild cognitive impairment — problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal aging.
Tag Archive | "FDA approval"
Aduhelm Targets Mild Cognitive Impairment: What Does That Mean?
Posted on 04 October 2021.
Posted in Health, Family CareComments (0)